We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Lipoprotein Receptor Mutation Linked to Increased Coronary Heart Disease Risk

By LabMedica International staff writers
Posted on 01 Jun 2015
A mutation caused by a single nucleotide polymorphism (SNP) in a cell membrane lipoprotein receptor has been linked to a significantly higher risk for developing coronary heart disease (CHD).

The lipoprotein receptor SR-BI (scavenger receptor class B, type I), which is encoded by the SCARB1 gene, is an integral membrane protein found in numerous cell types and tissues, including the liver and adrenal. More...
It is best known for its role in facilitating the uptake of cholesteryl esters from high-density lipoproteins (HDL) in the liver. This process drives the movement of cholesterol from peripheral tissues towards the liver for excretion. This movement of cholesterol is known as reverse cholesterol transport and is a protective mechanism against the development of atherosclerosis, which is the principal cause of heart disease and stroke.

Investigators at the University of Connecticut (Farmington, USA) examined the association of the SCARB1 rs4238001 missense SNP with incidents of CHD. For this work incidences of CHD were identified in a population of 2,319 White, 1,570 African-American, and 1,292 Hispanic-American participants in the 2000–2002 Multi-Ethnic Study of Atherosclerosis in Major American Cities study. The association of rs4238001 with incident CHD was determined after adjustments for age, sex, principal components of ancestry, body mass index, diabetes status, serum creatinine, lipid levels, hypertension status, education, and smoking exposure.

Results published in the May 20, 2015, online edition of the journal PLOS ONE revealed that subjects who were carriers of the risk T allele for rs4238001 had significantly lower SR-BI protein levels as compared with carriers of the normal allele. Moreover, in vitro experiments showed that the rs4238001 variant was significantly associated with increased degradation of SR-BI protein and reduced function as measured by decreased specific cholesteryl ester uptake from HDL.

The clinical study showed that the SCARB1 missense SNP rs4238001 was statistically significantly associated with incident CHD across a large population of multiple race/ethnic groups. In particular men with the variant had a 29% higher risk than a comparable group of men without. African-American males fared even worse, with 49% increase risk, as compared to white males.

"We want to go deep in the cell, and figure out how to repair it," said senior author Dr. Annabelle Rodriguez-Oquendo, professor of cell biology at the University of Connecticut. "We are really interested in understanding more about how this protein gets chewed up and degraded faster."

Related Links:

University of Connecticut



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.